ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?
Everything in China seems to be on the fast track. This is especially true in the pharma industry, where new announcements affecting regulations, pricing, and reimbursement are occurring on nearly a daily basis. How are Western pharma companies reacting to these changes? Is it going to be easier and faster to gain approval for Western drugs in China? Will this stimulate or impede local R&D and partnering activity?